This in-depth feature by Drug Discovery & Development traces Innophore’s journey from a 30-person Austrian startup to a strategic NVIDIA partner showcased at both the J.P. Morgan Healthcare Conference and CES. The article details how the Catalophore platform and NVIDIA’s BioNeMo framework are being combined to accelerate AI-driven drug safety screening and binding-site analysis, reducing computation times from thousands of CPU hours to minutes on GPU infrastructure.

Read the full article at Drug Discovery & Development